Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9150777 | 0.92 | SMN1; SMN2 (0.45) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9155117 | 0.90 | NPC1 (0.42) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL8189278 | 0.88 | PKM (0.47) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9158313 | 0.84 | — | — | |
| SCHEMBL7642011 | 0.81 | HTT (0.45) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9142828 | 0.81 | NPC1 (0.47) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9140427 | 0.81 | NPC1 (0.45) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9307402 | 0.79 | PKM (0.47) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9154452 | 0.79 | RECQL (0.46) | NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL9260108 | 0.77 | SMN1; SMN2 (0.48) | NPC1RAB9AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0514546-B1 | CHROMENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-04 | — | — | EP | claimed |
| US-5278186-A | Substituted with secondary amide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-01-11 | — | — | US | claimed |
| EP-0514546-A1 | CHROMENE DERIVATIVES, THEIR PRODUCTION AND USE. | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1992-11-25 | — | — | EP | claimed |
| WO-1991012249-A1 | CHROMENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-22 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |